Evidence map›Paper›PMID 30286784›Full record

ArticleOrphanet journal of rare diseases2018

The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage.

Anna Ambrosini, Daniela Calabrese, Francesco Maria Avato, Felice Catania, Guido Cavaletti, Maria Carmela Pera, Antonio Toscano, Giuseppe Vita, Lucia Monaco, Davide Pareyson

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07443449 (Connecting SBMA National Registries/Databases), which is not on this map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07443449 active not recruitingnot on this mapstarted 2024, after this paper: background citation

Connecting SBMA National Registries/Databases: a Retrospective Study

TypeobservationalSponsorFondazione I.R.C.C.S. Istituto Neurologico Carlo BestaRan2024 to 2026Enrolled700ConditionsSBMA, Spinal and Bulbar Muscular Atrophy (SBMA)
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. The Minimum Data Set for Rare Diseases: Systematic Review.Journal of medical Internet research · 2023
    Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Anna AmbrosiniFondazione Telethon, Via Poerio 14, 20129, Milan, Italy. aambrosini@telethon.it.ORCID 0000-0002-3065-975X
Daniela CalabreseUOC Malattie neurodegenerative e neurometaboliche rare, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Francesco Maria AvatoUniversity of Ferrara, Ferrara, Italy.
Felice CataniaAstir s.r.l., Milan, Italy.
Guido CavalettiSchool of Medicine and Surgery and Experimental Neurology Unit, University of Milano-Bicocca, Monza, Italy.
Maria Carmela PeraPaediatric Neurology and Centro Clinico Nemo, Catholic University and Policlinico Gemelli, Rome, Italy.
Antonio ToscanoDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Giuseppe VitaDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Lucia MonacoFondazione Telethon, Via Poerio 14, 20129, Milan, Italy.
Davide PareysonUOC Malattie neurodegenerative e neurometaboliche rare, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Fondazione IRCCS Istituto Neurologico Carlo Besta · ITTelethon Foundation · ITUniversity of Messina · ITAzienda Sanitaria Locale di Asti · ITCentro Clinico Nemo · ITUniversity of Ferrara · ITUniversity of Milano-Bicocca · IT

Funding

Fondazione Telethon GSP13002Fondazione Telethon GUP13006Fondazione Telethon GUP13013Fondazione Telethon GUP15009Fondazione Telethon GUP15010FP7 Research infrastructures 305444 RD-Connect
6 · The paper itself

Abstract

backgroundThe worldwide landscape of patient registries in the neuromuscular disease (NMD) field has significantly changed in the last 10 years, with the international TREAT-NMD network acting as strong driver. At the same time, the European Medicines Agency and the large federations of rare disease patient organizations (POs), such as EURORDIS, contributed to a great cultural change, by promoting a paradigm shift from product-registries to patient-centred registries. In Italy, several NMD POs and Fondazione Telethon undertook the development of a TREAT-NMD linked patient registry in 2009, with the referring clinical network providing input and support to this initiative through the years. This article describes the outcome of this joint effort and shares the experience gained.

methodsThe Italian NMD registry is based on an informatics technology platform, structured according to the most rigorous legal national and European requirements for management of patient sensitive data. A user-friendly web interface allows both direct patients and clinicians' participation. The platform's design permits expansion to incorporate new modules and new registries, and is suitable of interoperability with other international efforts.

resultsWhen the Italian NMD Registry was initiated, an ad hoc legal entity (NMD Registry Association) was devised to manage registries' data. Currently, several disease-specific databases are hosted on the platform. They collect molecular and clinical details of individuals affected by Duchenne or Becker muscular dystrophy, Charcot-Marie-Tooth disease, transthyretin type-familial amyloidotic polyneuropathy, muscle glycogen storage disorders, spinal and bulbar muscular atrophy, and spinal muscular atrophy. These disease-specific registries are at different stage of development, and the NMD Registry itself has gone through several implementation steps to fulfil different technical and governance needs. The new governance model is based on the agreement between the NMD Registry Association and the professional societies representing the Italian NMD clinical network. Overall, up to now the NMD registry has collected data on more than 2000 individuals living with a NMD condition.

conclusionsThe Italian NMD Registry is a flexible platform that manages several condition-specific databases and is suitable to upgrade. All stakeholders participate in its management, with clear roles and responsibilities. This governance model has been key to its success. In fact, it favored patient empowerment and their direct participation in research, while also engaging the expert clinicians of the Italian network in the collection of accurate clinical data according to the best clinical practices.

Indexed as

RegistriesDatabases, FactualHumansItalyNeuromuscular DiseasesRare DiseasesClinical networkNeuromuscular disordersPatient engagementPatient registries

Identifiers

PMID30286784
PMCPMC6172847
OpenAlexW2895544912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.